Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CGS 8515

Known as: CGS-8515 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Objective: The 5-lipoxygenase products, especially sulfidopeptide leukotrienes take an important role in the pathogenesis of… Expand
2004
2004
The o-naphthoquinone derivative, CGS 8515 (I), is a potent inhibitor (IC50, 0.1 µM) of 5-lipoxygenase, but its therapeutic… Expand
1995
1995
Effects of platelet-activating receptor antagonists WEB 2086 (1.0-30.0 mg.kg-1 intravenously) and BN 50730 (10.0 mg.kg-1… Expand
1993
1993
We evaluated the effect of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 alpha (IL-1 alpha) on pig cardiopulmonary… Expand
1992
1992
In the present study it was found that lipoxygenase inhibitors prevent LPS-, but not tumor necrosis factor alpha (TNF alpha… Expand
1989
1989
1. CGS 8515 selectively inhibited 5-LO (IC50 = 0.1 microM) with negligible effect on CO, 12-LO, 15-LO and TxS at concentrations… Expand
1988
1988
1 Ovalbumen (100μg)‐induced coronary vasoconstriction and decrease in cardiac developed tension were studied in isolated perfused… Expand
1988
1988
CGS 8515 inhibited 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 synthesis in guinea pig leukocytes (IC50 = 0.1… Expand
1988
1988
To determine the relative importance of arachidonic acid pathway products on vulnerability to ventricular fibrillation (VF), we… Expand